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Abstract
Homozygous loss of function (HLOF) variants provide a valuablewindow on gene function in humans, aswell as an inventory of
the human genes that are not essential for survival and reproduction. All humans carry at least a few HLOF variants, but the
exact number of inactivated genes that can be tolerated is currently unknown—as are the phenotypic effects of losing function
for most human genes. Here, we make use of 1432 whole exome sequences from five European populations to expand the
catalogue of known human HLOF mutations; after stringent filtering of variants in our dataset, we identify a total of 173 HLOF
mutations, 76 (44%) of which have not been observed previously. We find that population isolates are particularly well suited to
surveys of novel HLOF genes because individuals in such populations carry extensive runs of homozygosity, whichwe showare
enriched for novel, rare HLOF variants. Further, wemake use of extensive phenotypic data to show thatmost HLOFs, ascertained
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in population-based samples, appear to have little detectable effect on the phenotype. On the contrary, we document several
genes directly implicated in disease that seem to tolerate HLOF variants. Overall HLOF genes are enriched for olfactory receptor
function and are expressed in testes more often than expected, consistent with reduced purifying selection and incipient
pseudogenisation.
Introduction
The human genome contains more than 20 000 protein-coding
genes, but it is currently unknown how many of these genes
are essential for development, survival and reproduction, and
how many genes are, to some degree, ‘dispensable’. All humans
carry genetic variants predicted to cause loss of function (LOF) for
avariety of protein-coding genes, i.e. they carry frameshift or pre-
mature stop codon mutations in the coding regions of genes,
whole gene deletions, or splice site disruptions (1). In addition
it has been estimated that each human genome carries around
20 of these LOF variants in the homozygous state (HLOF), result-
ing in a naturally occurring ‘knockout’ of the gene concerned (2).
Compared with Mendelian disease variants, the phenotypic con-
sequences of such HLOF variants may often be small, though
HLOFs may have detectable effects upon more subtle pheno-
types. Under certain scenarios, loss of gene function can have
protective effects against disease, and such genes are of particu-
lar interest as novel therapeutic drug targets. For example, HLOF
at PCSK9 can lead to reduced levels of LDL cholesterol (3), HLOF at
SLC30A8 is protective for type 2 diabetes (4) and a homozygous
partial deletion of CCR5 protects against HIV infection (5,6).
Previous efforts have been made to catalogue HLOF variants
in human populations (2,7), identifying a total of 253 and 169
homozygous loss of function genes within cosmopolitan indivi-
duals and individuals with consanguineous parents, respectively.
Most HLOFswere present at very low frequencies, but the number
of HLOFs per individual was higher in the study of offspring from
consanguineous marriages and associated with high levels
of homozygosity genome-wide (7). Only a modest overlap was
evident between the genes identified in these two studies [only
one-third of the HLOFs of (7) were also found by (2)], suggesting
that many HLOFs are population-specific and that awider variety
may be discovered across diverse populations.
A recurring complication in the identification of HLOF var-
iants is a high rate of false positives, caused by variants that
are either sequencing errors or variants wrongly annotated as
HLOFs. Sequencing errors are expected to occur relatively uni-
formly across the genome, but the proportion of true variation
at highly constrained sites is expected to be much lower than at
functionally neutral sites, i.e. a high proportion of sequencing er-
rors can spuriously appear as HLOF variants (8), and further
biases are introduced by the fact that HLOF mutations often
occur at low allele frequencies (9,10). However, even if a HLOF
variant is correctly called, some seemingly damaging mutations
may have little effect on the function of the protein if they can be
rescued by other, nearby variants, or if they occur in more ‘dis-
pensable’ sections of a protein, such as those in rare isoforms
or HLOF mutations at the end of an open reading frame. Hence,
strenuous filtering and validation of putative loss of function var-
iants is essential.
Population isolates provide natural laboratories for studying
the roles of rare variants in complex phenotypes because the
population’s evolutionary history may often lead to relatively
high frequencies of rare homozygous variants. On the one
hand, population isolation leads to increased levels of back-
ground relatedness and inbreeding, which increases levels of
homozygosity; in addition, genetic drift is stronger in small
populations, which can lead to a higher frequency ofmildly dele-
terious variants, such as LOFmutations, in small or bottlenecked
populations (11). Indeed, a recent study found a significant en-
richment of low frequency LOF variants in the Finnish population
relative to other Europeans, and, by making use of phenotype
data in 36 262 individuals, they could identify variants affecting
quantitative traits (12).
In this study, we used exome sequencing in four European
isolate populations spanning the continent and a collection of
more cosmopolitan Scottish samples from the Generation Scot-
land: Scottish Family Health Study (GS:SFHS) (13). For the first
time we are able to examine the frequencies of HLOF variants
across isolate populations sampled from diverse sites across Eur-
ope and compare them to a national collection. Using exome data
for a total of 1432 individuals, we identify 94 validated premature
stop-gain and 79 frameshift variants; a total of 76 of which had
not been observed in previous surveys (2,7), including the pub-
lished variants of a study of Finnish and non-Finnish Europeans
(12). We find a higher prevalence of HLOF variants in the isolates,
and find that novel HLOFs are significantly enriched in these po-
pulations. We also exploit phenotypic data, to explore the effects
of HLOF variants on hundreds of clinically relevant quantitative
traits across many physiological areas. We find that HLOFs in
our dataset generally have little effect on phenotype and appear
to constitute largely neutral variation.
Results
Across the 1432 exomes, 1 465 905 indels and single nucleotide
polymorphisms (SNPs) passed the GATK default filters. These in-
cluded predicted 1084 stop-gain and 1185 frameshift variants
that were homozygous in at least one individual. However, the
majority of these apparent HLOF variants were likely to be
second-generation sequencing errors, rare errors in the reference
genome or variants that do not disrupt gene function. Conserva-
tive filtering and additional conventional Sanger sequencing of
variants led to the exclusion of most SNPs and indels from our
analysis, reducing the number of homozygous stop-gains to 94
and the number of frameshifts to 79. In particular, Sanger se-
quencing revealed the importance of sequence coverage in vari-
ant calling accuracy (Supplementary Material, Fig. S1), and we
conservatively set the minimum coverage for novel variants,
not previously observed (2,7) to 20×. In addition, we removed
three variants that were fixed or nearly fixed in all populations
(only one heterozygote was observed for one of the three var-
iants, all other sites were non-reference), assuming that these
are either errors or rare variants in the reference sequence (at
hg19 positions chrX:82764038; chrX:104464281; chr11:104763117).
The number of variants that were removed by each of our filters
is shown in Table 1.
Thirty-three variants were selected for Sanger sequencing
based on their complete novelty or because they were present
in dbSNP, but without validation status. Interestingly, among
the 13 HLOF variants that were confirmed by Sanger sequencing
as true positives, nonewere specific to the cosmopolitan GS:SFHS
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population, whereas 9 were found exclusively in the isolates
(CROATIA-Vis, CROATIA-Korčula, NSPHS, ORCADES), at very low
frequencies (Table 2). This is despite a lower number of indivi-
duals that were sequenced in isolate populations—588 in isolates
versus 844 individuals in GS:SFHS—suggesting an enrichment of
rare, novel HLOFs in isolate populations (Fisher’s exact test, P <
0.01). Note that the variant at chr6:31106500 had a dbSNP valid-
ation record but was included in the Sanger-sequencing as a con-
trol; this variant was observed in four populations. Given that the
Sanger sequenced variants were a priori expected to be enriched
for false positives, their low validation rate is not too surprising.
Among the 20 variants that failed validation by Sanger sequen-
cing, 12 were completely absent (9 erroneously called stop-
gains and 3 frameshifts); a further 3 frameshift variants were in
fact heterozygous, and 2 deletions turned out to remove a mul-
tiple of 3 base pairs; 3 sequences were not clean or gave ambigu-
ous sequencing results and were conservatively excluded. Other
than low sequence coverage of these 20 variants, however, there
were no indications as to why high throughput sequencing had
given erroneous results.
Individuals from population isolates tend to carry longer runs
of homozygosity (ROHs) comparedwithmore cosmopolitan indi-
viduals (14). Rare HLOFs are expected to be enriched within ROHs
because they represent regions that are identical-by-descent,
that is, inherited from the same common ancestor (7); thus,
rare variants, which would otherwise not be found in the homo-
zygous state, are brought together (15).
To test this, we assessed, for each HLOF and carrier, whether a
variant was found within or outwith a run of homozygosity
(ROH). We then calculated the overall frequency of HLOFs
which fell within ROHs; this value differed among populations
(3% of HLOFs in GS:SFHS were found within ROHs, whereas it
was 10% in CROATIA-Korčula; 8% in NSPHS; 7% in CROATIA-Vis;
6% in ORCADES), reflecting the different overall proportions of
the genome that are found within ROHs in isolate versus our
cosmopolitan sample (14) (Fisher’s exact test comparing the
number of HLOFs inside and outside ROHs in GS:SFHS versus
each isolate population: P < 0.01 in each comparison). Singleton
HLOFs that were observed only once across all populations were
foundmore oftenwithin ROHs (15 out of 48HLOFs = 31%)—and all
seven novel singletons identified in this study fell within ROHs.
Importantly, HLOF variants thatwere biased towards being inside
ROHs had lower allele frequencies compared with variants that
were mostly found outside ROHs (Fig. 1), suggesting that rare
HLOFs can be found more easily in individuals with increased
homozygosity.
Table 3 shows the number of HLOF variants found in each of
the five populations. Notably, the yield of HLOF variants, i.e. the
number of observed HLOFs per number of individuals sampled,
was much higher for the isolates compared to GS:SFHS: 0.52 to
0.93 compared with 0.16 per individual, respectively. However,
the average burden (i.e. number of HLOFs) did not differ between
GS:SFHS and the isolates: each individual carried amedian num-
ber of nine HLOFs in GS:SFHS, NSPHS and ORCADES; the median
number of HLOFs was 10 in CROATIA-Vis and seven in CROATIA-
Korčula (Fig. 2). Note that the lower value in CROATIA-Korčula
was probably caused by the lower sequence coverage for samples
from this population, resulting inmore sites being excluded from
the analysis. Hence, even though individuals from isolate popu-
lations did not carry a higher absolute number of HLOFs, the mu-
tational spectrum that was captured differed, resulting in an
enrichment of rare (and thus potentially more likely to be func-
tional) HLOFs in isolates.
To assess the predicted consequences of our HLOF variants,
we examined their C-scores (16), which indicate the ‘deleterious-
ness’ of a given (multi)nucleotide change. HLOF variants were
found to possess C-scores between 1.4 and 44.0, with an overall
median score of 18 (Fig. 2). In comparison, the top 1% of deleteri-
ous variants in the genome are assigned a score of ≥20; the pre-
dicted median C-score of nonsense variants within known
disease genes (defined as genes that harbour at least five
known pathogenic mutations) is 37 (16,17). In our dataset, the
maximum C-score of 44 was found in a variant within the
WDR87 gene on chromosome 19 (rs151219712), whichwas homo-
zygous in a single individual from GS:SFHS (Supplementary
Table 2. Sanger-sequencing confirmed HLOFs
Position Gene Number of
homozygotes
Population
chr1:55076137 FAM151A 1 NSPHS
chr4:113539281 C4orf21 1 CROATIA-Korčula
chr5:96222446 ERAP2 1 CROATIA-Vis
chr6:28358464 ZSCAN12 1 CROATIA-Vis
chr6:31106500 PSORS1C1 26 CROATIA-Vis,
ORCADES,
GS:SFHS, NSPHS
chr12:70088219 BEST3 2 CROATIA-Vis,
ORCADES
chr14:57672624 AL391152.1 2 NSPHS, GS:SFHS
chr15:44091290 SERINC4 1 CROATIA-Vis
chr17:46882286 TTLL6 2 CROATIA-Vis,
GS:SFHS
chr17:47921435 TAC4 1 CROATIA-Vis
chr19:36230499 IGFLR1 1 ORCADES
chr19:51729103 CD33 3 NSPHS, GS:SFHS
chrX:50659021 BMP15 1 ORCADES
The number of individuals which were homozygous for a novel, Sanger-
sequencing confirmed variant, and the population where the variant was found.
Table 1. Filtering putative HLOF variants
Filter Stop gain
mutations
Frameshift
mutations
Total number of variants before filtering 1084 1185
Relative_position < 0.9 883 973
Duke (mapability) 960 1027
DAC excluded regions (mapability) 1083 1175
CRg (mapability) 893 917
Min. 200 945 942
SureSelect & TrueSeq 794 829
Ancestral allele 1032 NA
MNP/frameshift nearby 982 817
Hardy–Weinberg 323 373
All filters applied, Sanger Sequencing 94 79
The number of putative HLOF variants remaining after each mutational filter had
been applied individually. Filters have the following meaning: ‘Relative_position
< 0.9’ indicates that variants are limited to the first 90% of all splice variants of a
gene. ‘Duke’, ‘DAC’ and ‘CRg’ are mapability scores of UCSC. ‘Min.200’ indicates
that at least 200 individuals were sampled for each variant. ‘SureSelect &
TrueSeq’ is the intersection of the two exome sequencing kits. ‘Ancestral allele’
indicates whether the LOF variant is found in other primates. The ancestral
allele filter was applied to frameshift mutations only after all other filters had
been applied, leading to the exclusion of seven variants. ‘MNP/frameshift
nearby’ indicates whether a restoring variant was found in proximity of the
focal variant. ‘Hardy–Weinberg’ indicates whether the variant passed our
Hardy–Weinberg filter.
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Material, Table S1). The median C-score of our novel, Sanger se-
quencing-confirmed, variants was 20.0; this is not significantly
different from that of the remaining, previously known, variants,
which had a median score of 18.0 (Wilcoxon test: W = 1041.5;
N.S.). However, there was a negative correlation between the
C-score and the number of individuals carrying a HLOF variant
(Spearman’s rho = −0.30; P < 0.05), consistent with the extent of
purifying selection on a variant being reflected, to some extent,
by the number of times an HLOF is observed.
Gene Ontology analysis using GOrilla (http://cbl-gorilla.cs.
technion.ac.il/ accessed September 2014) (18) revealed an excess
of transmembrane signalling receptor genes amongst HLOF
genes, including olfactory receptor genes (Table 4). Indeed, olfac-
tory receptor genes have previously been shown to be over-repre-
sented among HLOF genes (2), and segregating polymorphisms
of functional and non-functional copies of olfactory genes
are common (19). Although no other GO category was over-repre-
sented among the HLOF genes discovered here, a large number of
HLOF genes were expressed in testis: across 16 tissues sampled,
expression was highest in testis for 28.7% of HLOF genes, i.e. for
41 out of the 143 HLOF genes that were present in the EBI
Figure 1. Rare HLOFs are found within ROHs. Allele frequencies of HLOFs that are biased towards being inside or outside runs of homozygosity (ROHs) in the five
populations studied (using a binomial test with P < 0.1). For GS:SFHS, CROATIA-Vis, ORCADES and NSPHS, the allele frequencies of variants that were enriched in
ROHs were significantly lower compared with variants that were found in the autozygome (Wilcoxon test; P < 0.05). In CROATIA-Korčula, only two variants were
underrepresented in ROHs, and the Wilcoxon test was not significant.
Table 3. Summary of the numbers of HLOFs found
Population N N(HLOFs) Yield Private
LOFs
Private
HLOFs
GS: SFHS 844 137 0.16 1 26
CROATIA-Vis 193 104 0.54 2 8
ORCADES 197 103 0.52 3 13
NSPHS 98 91 0.93 0 6
CROATIA-Korčula 100 74 0.74 1 4
The sample size, N, and the number of HLOF mutations that were found in each
population, N(HLOFs); the average yield per individual (N(HLOFs)/N); the extent to
which themutations are shared across populations. Private LOFs are seen only in
one population, including as heterozygotes; private HLOFs are shared as
heterozygotes across populations.
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expression atlas (http://www.ebi.ac.uk/gxa/ accessed September
2014) (20,21). The proportion of testis-expressed genes amongst
all genes sampled was also higher for the HLOF genes (119 out
of 143 genes = 83%) compared with the overall expression profile
of human protein-coding genes (77% of all human transcripts
detected by (22) were found in testis, with 10% being enriched
in testis). This apparent loss of function at testis-expressed
genes is consistent with a recent study (23), which showed that
male-specific genes in humans carried a relatively high load of
deleterious polymorphisms, possibly due to reduced selection
on these variants in females who do not express these genes.
Only nine HLOF genes discovered here are annotated as dis-
ease-associated in the scientific literature, with an entry in the
OMIM database (http://www.omim.org/ accessed November
2014), indicating the relatively low impact of HLOFs found in
healthy individuals. Further, it should be noted that most
Figure 2. Number of HLOFs per individual and predicted deleteriousness. Boxplot of the number of HLOFs carried by each individual in GS:SPHS, CROATIA-Vis, CROATIA-
Korčula, ORCADES and NSPHS (A) and the C-scores associated with HLOF variants in the five populations (B).
Table 4. Gene Ontology
GO term Description FDR adjusted q-value Enrichment (N, B, n, b)
GO:0004984 Olfactory receptor activity 3.35E-11 7.65 (17 424,362,151,24)
GO:0004930 G-protein coupled receptor activity 7.86E-06 3.81 (17 424,788,151,26)
GO:0004888 Transmembrane signalling receptor activity 8.29E-04 2.80 (17 424,1154,151,28)
GO:0004872 Receptor activity 8.60E-04 2.52 (17 424,1464,151,32)
GO:0038023 Signalling receptor activity 2.50E-03 2.58 (17 424,1253,151,28)
GO:0004871 Signal transducer activity 9.62E-02 2.09 (17 424,1548,151,28)
GO:0060089 Molecular transducer activity 8.25E-02 2.09 (17 424,1548,151,28)
GO analysis of genes containing HLOF variants, using, as a background set, all genes captured by the intersection of the SureSelect and TruSeq exome sequencing kits.
Enrichment = (b/n)/(B/N); N = Number of genes; B = Number of genes associated with a GO term; n= number of genes in the target set; b = number of genes in the
intersection.
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OMIMgenes in our dataset were associatedwith risk phenotypes,
rather thanMendelian diseases: BTNL2,CARD14, TLR5 andARMS2
were associated with susceptibility to sarcoidosis, psoriasis or le-
gionnaire disease and late onset macular degeneration, respect-
ively; RNF212 was associated with a non-risk phenotype,
variation in recombination rate (Supplementary Material,
Table S1).
Awide range of phenotypic measurements were available for
individuals from the five populations studied (Supplementary
Material, Table S2). However, there was no evidence for any vari-
ant possessing a measurable effect, including four variants in
known disease genes:
The Macrophage Scavenger receptor 1 (MSR1, also known as
SRA) is an LDL receptor, and is implicated in the pathologic de-
position of cholesterol in arterial walls (24,25). A single individual
(a 68 year-old female from CROATIA-Vis with a body mass index
of 24.5) carried a HLOF in MSR1; this variant had not previously
observed as a homozygote (2,7,12), and it was associated with a
high C-score (38.0). However, the individual showed no suspi-
cious phenotype, and her serum lipid levels were normal (total
cholesterol 5.7 mmol/l; HDL 1.92 mmol/l; LDL 1.48 mmol/l), sug-
gesting that losing function at the MSR1 gene does not have
major effects on blood lipid levels.
Bone morphogenetic protein 15 (BMP15) is an X-linked gene,
which is exclusively expressed in ovaries, in the oocytes of late pri-
mary follicles (26), and it is associated with infertility and ovarian
dysgenesis (OD), even in heterozygotes (27–29). In our dataset, we
found a rare LOF variant in BMP15 in ORCADES: in the exome se-
quence dataset, a single male carried a (hemizygous) LOF frame-
shift variant in the mature protein-coding region of BMP15,
upstream of the missense mutation described previously (29).
The same variant was also found in the heterozygous state in
threeORCADES females, but innoother population.WeSanger se-
quenced these 4 individuals, as well as 33 additional Orcadians
from the ORCADES study, all of whom were first, second or third
degree relatives of the 4 known carriers. Supplementary Material,
Table S3 shows their genotypes and the number of offspring: we
never observed the frameshift variant in the homozygous state
in females; and of the five heterozygous females, two had chil-
dren. Further, the variant was present on the single X chromo-
some in nine males (whose mothers must have carried the
variant on at least one X), so we can conclude that the frameshift
variant does not lead to OD in heterozygotes.
Among the HLOF variants in genes with OMIM entries, two
variants might be rescued by alternative transcripts and reading
frames. PDE6G, the first of these genes, encodes one of the three
subunits of Cyclic GMP-phosphodiesterase (PDE), and incorrect
splicing of the gene is reported to lead to early-onset retinitis pig-
mentosa in a family-based mapping study (30). In our dataset, a
HLOF was observed in six individuals, but the four carriers who
were scored for eye phenotypes (from CROATIA-Vis, CROATIA-
Korčula and ORCADES) did not show any abnormalities. How-
ever, the frameshift variant was detected in only one of the five
alternative transcripts for this gene, and function may be re-
stored by the presence of alternative transcripts for which the
variant is intronic and in the 5′ UTR respectively. Similarly, var-
iants in SERAC1 are thought to cause a severe Mendelian pheno-
type (MEGDEL syndrome), which includes encephalopathy,
dystonia and deafness (31). We find a HLOF in a single individual
from CROATIA-Vis—a healthy 33 year-old male who showed no
unusual phenotype. However, SERAC1 has several transcripts in
two different reading frames, and the stop-gain variant occurs
a reading frame, which is expected to lead to nonsense-mediated
decay (in transcripts ENST00000607071, ENST00000607742,
ENST00000606965). The same variant is merely a missense vari-
ant on exon 4 of the transcript (ENST00000367104), i.e. outside
the lipase/esterase domain, which is implicated in causing MEG-
DEL syndrome when disrupted (31).
In all of the five populations, the number of HLOFs for a given
individual (which ranged from 0 to 18)was not a good predictor of
the observed number of outlier traits per individual, i.e. the num-
ber of trait values in the top or bottom 1% of the population
(which ranged from zero to 211); this result remained unchanged
also if only strongly deleterious HLOFs (C-score >25) were
included in the analysis, or if olfactory genes were excluded
(Supplementary Material, Table S4). If the majority of genes con-
taining HLOF variants do not have measureable phenotypic
effects, this could be due to a higher than usual number of para-
logues for these genes, i.e. genes belonging to the samegene fam-
ily could act as a buffer on the effect. This, however, does not
seem to be the explanation: when olfactory geneswere excluded,
the number of paralogues for HLOF-containing geneswas actually
lower compared with protein-coding genes in the genome as a
whole (Wilcoxon test, 70% identity cut-off for paralogues: P < 0.05;
Wilcoxon test, 80% identity cut-off for paralogues: P < 0.01). Fur-
ther, the number of one-to-one orthologues with mouse and
chimp did not differ between the set of HLOF genes and all
human protein-coding genes on Ensemble (Chi-square test
with Yates’s correction: N.S. for both comparisons).
Discussion
Using exome sequences from 1432 individuals, we extend the
known repertoire of human genes that are dispensable, i.e.
genes that can carry homozygous loss of function variants in
healthy individuals. The vast majority of these genes do not
have strong phenotypic effects, i.e. they seem to be truly dispens-
able. Further, all but seven HLOF variants are shared across the
five European populations as heterozygotes (Table 3), i.e. most
HLOFs are relatively old and hence unlikely to be strongly dele-
terious. In line with this, the predicted deleteriousness of HLOF
variants is, on average, lower than that of predicted disease var-
iants. However, we do find the isolate populations to be enriched
for homozygous LOF variants of low frequency because rarer var-
iants are relatively more likely to be brought into the homozy-
gous state within the long ROHs present in these populations.
Accordingly, population isolates are a good place to look for
novel HLOF variants. Of course, it would be advantageous to
extend the search for HLOF genes beyond those of European heri-
tage populations, especially those with high levels of homozy-
gosity: extended ROHs have been found in other worldwide
populations, such as Native American and Oceanian populations
(32,33); homozygosity in these populations is presumably caused
by bottlenecks and haplotypes randomly drifting to a high fre-
quency. Even longer ROHs tend to be found in the Near and Mid-
dle East, which has a history of recent consanguinity, and has
already been used to study HLOFs (7). Intriguingly, the distribu-
tion of ROHs among populations is non-uniform (32): first, this
might simply be due to chance, i.e. rare recombination events
can break up different associations in different populations; in
addition, regions of high levels of homozygosity often overlap
with loci of recent positive selection—which are often popula-
tion-specific and include loci such as the human skin pigmenta-
tion gene, KITLG (32). Presumably, rare HLOF variants are
enriched in segments of recent positive selection, for example,
due to genetic hitch-hiking (34). The best way to find these var-
iants is by sequencing more individuals from a broader geo-
graphical spectrum, focussing on isolated populations that are
Human Molecular Genetics, 2015, Vol. 24, No. 19 | 5469
Downloaded from https://academic.oup.com/hmg/article-abstract/24/19/5464/583958
by Max-Delbruck-Center for Molecular Medicine user
on 03 August 2018
geographically distant from Africa and/or populations that have
experienced recent inbreeding.
Overall, we find a similar total number of HLOF variants as a
study of consanguineous individuals (7), but many fewer than a
large study of cosmopolitan individuals (2). This may be partly
due to a slightly different set of filters applied; some of our filter-
ing was very conservative, and this might have led to a relatively
higher rate of exclusion of true variants. For example, neither of
the two other studies removed variants that showed an excess of
homozygous LOF variants in the population (the Hardy–Wein-
berg filter), but we show that this filter is indeed a good indicator
of an erroneous SNP call. Further, we excluded all HLOF variants
that occurred in the last 10% of any transcript of a gene, whereas
the 1KG study (2) removed variants if they were found in the last
5% of the longest transcript for a particular gene. We also applied
a mapping-based filter, i.e. the ‘uniqueness score’ of the UCSC
genome browser, which had not been used before; further, the
prior cosmopolitan survey also included splice sites and dele-
tions in their set of HLOFs (2), which increases the overall number
ofHLOFs they report. Indeed, 29HLOF variants of the consanguin-
eous dataset (7) were removed by our approach, and 203 variants
in the 1KG dataset (2) were removed from our homozygous set of
LOFs; note that this included variants thatwere seen as heterozy-
gotes in the 1KG data (2).
Despitedifferences inapproach, it becomes clear thatHLOFvar-
iants are relatively common amongst healthy individuals, with
each individual carrying about 10–20 HLOFs, and many seemingly
deleteriousmutations canbe tolerated. Even though these variants
may not have any measurable effect, cataloguing them will help
identifying rare mutations, which do cause severe phenotypes
and diseases, by acting as negative controls. Of course, the effect
of losing function at a given genemay also depend on the genomic
background, i.e. other variants present in the same genome, and
therefore dispensability may be a complex phenomenon.
In addition, disruptive mutations affecting the same gene
may not always have the same phenotypic consequences, as out-
lined in our study of BMP15: In a previous study (29), a rare, het-
erozygous, missense mutation was shown to lead to OD due to
abnormal processing of the precursor BMP15 protein, which re-
sulted in precursor dimers and/or precursor-mature peptide het-
erodimers. Importantly, the missense mutation reported in (29)
was associated with reduced granulosa cell growth even in the
presence of wild-type BMP15, i.e. in heterozygous assays. How-
ever, Orcadian females, who are heterozygous for the novel mu-
tation described here, are fertile—even though their frameshift
variant is upstream of the previously described missense muta-
tion. There are two possible explanations to this. First, in contrast
to the missense mutation, the frameshift variant will lead to a
completely altered protein sequence and structure. Accordingly,
oocytes will be completely free of abnormal BMP15 hetero-di-
mers in heterozygotes, of the kind that had been observed before
(29), i.e. losing one copy of BMP15might be less deleterious than
havingone copy that is compromised in its function.Alternatively,
given that genes in the vicinity BMP15 are subject to X-inactiva-
tion (35) and silencing of one X often occurs in a block-wise and
skewedmanner (36), it is possible that the copy of BMP15 contain-
ing the frameshift variant becamepreferentially silenced inOrca-
dian females, whereas themissensemutationwas expressed to a
greater extent in the heterozygous females who developed OD.
Accordingly, the genomic context and exact type of mutation
may ultimately affect the phenotypic outcome for loss of func-
tion variants.
Our results suggest that buffering by paralogues genes cannot
explain the presence of the HLOF variants because we actually
observe a dearth of paralogues for HLOF genes. Partly, this may
be explained by our mutational filter, which removed variants
in non-unique genomic regions. However, it remains possible
that HLOF genes are dispensable for other reasons, such as buf-
fering by unrelated genes of similar function, or that function is
rescued by alternative transcripts of the same gene; note that
only 35 HLOF variants were present in all reported isoforms of a
given gene, and 48 variants were observed in only one of two or
more alternative transcript (Supplementary Material, Table S1).
Further, phenotypic effects may not be picked up by our broad
survey or are too subtle to be detectable when there are typically
only one or two carriers: While it is relatively straightforward to
show that a given HLOF does not inevitably cause a severe dis-
ease, it requires a large sample sizes and replicated studies to
demonstrate variant-trait associations for quantitative traits.
Accordingly, with hundreds of phenotypic traits measured for
GS:SFHS and the isolate populations, we were able to search for
phenotypic outliers; however, given the often small number of
individuals carrying a given HLOF, we lacked statistical power
to find genotype-phenotype associations in our dataset, which
is a general caveat when studying rare variants with small
effects.
This project is part of a current effort to catalogue and under-
stand the impact of naturally occurring loss of function muta-
tions in humans. Another possible field of research—loss of
function at regulatory elements—has so far been neglected in
population surveys, even though the effects of variants at non-
coding sequence may potentially be just as severe as those in
translated regions. This is certainly an area that will become
more accessible with whole genome sequencing becoming
cheaper—though the associated computational challenges will
be even greater.
Materials and Methods
Weusedwhole exome sequences fromGS:SFHS (13) and four iso-
late populations: two Croatian Islands (CROATIA-Vis and CRO-
ATIA-Korčula) (37,38), the Northern Swedish Population Health
Study (NSPHS) recruited in the northernmost two counties of
Sweden (39) and the Orkney Complex Disease Study (ORCADES),
sampled in the Orkney Isles (Orcadians) (37). Originally, these in-
dividuals had been recruited for population-based studies of
complex traits, i.e. a range of phenotypic data had been collected,
including anthropometry, lipids, glycaemic traits, body compos-
ition, blood biochemistry, glycomics, cognitive function, etc.
(Supplementary Material, Table S2). Notably, these individuals
were generally healthy (from population-based sampling), ex-
cept for some in the GS:SFHS cohort, which included obese indi-
viduals, as well as individuals with major depression. The
Generation Scotland cohort 1 (GS:SFHS 1) contains 432 samples
that were sequenced at the GenePool facility (University of Edin-
burgh) using the Illumina TruSeq capture kit (Illumina, CA, USA)
with a mean coverage per sample of ∼38×. Generation Scotland
cohort 2 (GS:SFHS 2) contains 428 samples that were sequenced
at theWellcome Trust Sanger Institute, as part of the UK10K pro-
ject, using the Agilent SureSelect capture kit v3 (Agilent Tech-
nologies, CA, USA), with a mean coverage of ∼86×. A total of 588
individuals were sequenced from isolate populations: 193 from
CROATIA-Vis, 107 from ORCADES, and 98 from NSPHS were se-
quenced at theWellcomeTrust Sanger Institute using the Agilent
SureSelect capture kit v3 with a mean coverage of ∼59×. Ninety
ORCADES samples and 100 from CROATIA-Korčula were se-
quenced at Source Biosciences, Nottingham, using the Agilent
SureSelect v2 kit with a mean coverage of 30×.
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Reads were aligned to the human reference genome GRCh37
using bwa (version 0.62 for CROATIA-Korčula and version 0.59
for all other samples) (40). For each aligned sample, duplicate
reads were marked with Picard (version 1.79), and Samtools
0.1.16 (41) was used at various points along the analysis pipe-
line, e.g. the merging or indexing of bam files. Realignment
around insertions/deletions (indels), base quality score recali-
bration and variant discovery were performed using the Gen-
ome Analysis Tool Kit (GATK) 2.7.2, according to GATK best
practice recommendations for exome sequence analysis
(42,43). Variant discovery was carried out for the target inter-
vals covered by either TruSeq or SureSelect, with an additional
50 bp of padding around the target regions. SNP and indel call-
ingwas performedwithUnifiedGenotyper, using reduced align-
ments and downsampling (to 250) across all 1432 samples
simultaneously. Variant recalibration was performed with
GATK version 2.8.1 and dbSNP version 137 was used throughout
this pipeline.
Bam and vcf files were submitted to the European Nucleotide
Archive (ENA) at the European Bioinformatics Institute (http://
www.ebi.ac.uk/), with accession numbers XXX (to be added
upon publication).
We extracted all sequence variants (SNPs or indels) which
passed the GATK recalibration, showed a homozygous non-refer-
ence allele in at least one individual and were predicted to intro-
duce premature stop-gain or a frameshift into the coding region,
as determined by the variant effect predictor (44), using Ensembl
75 genemodels. We did not consider splice disruptionmutations
since they would have required validation using expression data
in multiple tissues. Multi-allelic variants were separated out into
their respective variants using bcftools, and the remaining
homozygous stop-gain and frameshift variants constituted our
pool of putative HLOF mutations.
Next, variants were subjected to a range of filters, in order to
remove false positives due to sequencing and variant calling er-
rors, annotation errors, as well as variants that are unlikely to
cause a true loss of function to the protein (Table 1). In particular,
because of the expected high rate of false positives in the initial
dataset, we set our filters to be very conservative, and describe
these in the following.
Protein sequences for transcripts affected by putative stop-
gain or frameshift mutations were downloaded from Ensembl
biomart (http://www.ensembl.org/biomart, accessed June 2014),
and the relative position of the variants assessed. Variants
often clustered near the end of the end and beginning of a tran-
script (Supplementary Material, Fig. S2), reflecting reduced func-
tional consequences for variants located in the extreme and of a
reading frame, alternative start codons (2), or a lower sequence
coverage near the start codon. We only kept variants if they fell
into the first 90% of all transcripts annotated for a particular
gene; notably, the excess of variants near the start codonwere re-
moved by other filters that we applied.
In order to avoid spurious calling of SNPs due to mapping of
reads from paralogous genomic regions, we downloaded UCSC
tracks of Crg (36mer) and Duke (35mer) Alignability scores, as
well as DAC blacklisted regions; SNPs and indels that fell into
non-unique regions of the genome (with Alignability scores
<1.0) were excluded from further analyses, as were variants with-
in in UCSC blacklisted regions.
To remove sites that are potentially difficult to sequence and
hence more prone to sequencing or alignment errors, we re-
stricted our set of HLOF variants to sites that were called in at
least 200 individuals, and, to make a comparison possible across
populations, we only considered sites thatwere captured by both
exome capture techniques (TrueSeq and SureSelect), plus 50 bp
of padding around the target region.
By the intersection, the target regionwas reduced from a total
of 51.5 MB (for SureSelect) and 62.1 MB (TruSeq) to 33.4 MB.
We excluded variants that were also found in the genome as-
semblies of primate outgroup species (chimp, gorilla, orang-
utan). These variants are potentially mis-annotated in the
human genome (e.g. due to sequencing errors), or the variant
that we detect might be an ancient polymorphic stop loss muta-
tion in the primate lineage. For the primate comparison, verte-
brate multiZ alignments were downloaded from the UCSC
genome browser, and the human variants were compared to
those in the other three primate species. To allow for alignment
ambiguity in the case of frameshift variants, 5 bp upstream and
downstream of an indel were extracted and compared. A frame-
shift was filtered out if (1) at least two primates had aligning se-
quence present in the region, (2) all species, which showed an
alignment, carried the non-reference variant and (3) the position,
length and type (insertion or deletion) of the primate variant
matched the one seen in humans (according to (2)). Stop-gain
variants were filtered out whenever one or more of the primate
species carried the human non-reference allele.
Multinucleotide polymorphisms (MNPs), i.e. variants that
consist of two or more adjacent SNPs, were filtered out if a
stop-gain variant was found within the same codon as another
SNP. For frameshift variants, the corresponding filter was slightly
more sophisticated. In the simplest case, a transcript contained
only a single frameshift variant, which was then kept. Frame-
shifts were also kept for further analyses if (a) a transcript con-
tained two or more homozygous frameshift variants that were
separated by 10 or more amino acids in the translated protein
or (b) nearby frameshift variants (<10 amino-acids apart) did
not result in a restoration of the reading frame, i.e. the sum of
bases inserted or deleted was not amultiple of three. In contrast,
frameshift variants were filtered out (i) if two nearby variants re-
sulted in the restoration of the reading frame or (ii) whenever
three or more frameshifts occurred within close vicinity of each
other because insertions or deletions resulting in triplets were
possible for these variants.
The high false positive rates due to sequencing errors among
LOF mutations can, at least partially, be corrected by considering
the overall allele frequencies and contrast these with the fre-
quencies of homozygous versus heterozygous individuals within
a population, i.e. testing for Hardy–Weinberg equilibrium (HWE).
Accordingly, we filtered out any putative LOF variants that were
found in more homozygous individuals than expected under
HWE in any of the five population samples considered separately
(with a P-value <0.01). This approach is based on the assumption
that loss of functionmutations arenot subject topositive selection,
i.e. they are either removed by selection (leading to a reduction in
the number of homozygotes) or effectively neutral. An excess of
homozygotes can also be observed when there is population
substructure; however, as a control, we show that the variants
confirmed previously (2,7) had fewer deviations from HWE than
our unfiltered, raw variants (Supplementary Material, Fig. S3),
which iswhywe conservatively applied the Hardy–Weinberg filter.
For the allele frequency calculations, we included all individuals
with a coverage of at least 5×; however, to be kept in the analysis,
a variant had to be observed in a homozygous state in at least
one individual with a coverage of 20×.
Last, to validate our filtered set of HLOF variants, we Sanger-
sequenced any novel variants that we detected in our samples;
these included 33 variants which were neither found in the set
of HLOF variants of (2) nor (7), and had no validation record in
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dbSNP. Note that these variants constitute the set of variants that
is, a priori, most biased towards containing false positives. Pri-
mers were designed within ∼400 bp surrounding each loss of
function variant using Primer3 (45,46). Sequences were amplified
by PCR and bidirectional sequencing performed using N13 pri-
mers and a Big Dye Terminator Cycler Sequencing kit v1.1 (Ap-
plied Bio-systems, Warrington, UK). Results were compared
with the reference sequence (NM_000545.3) Sequencher v4.8
(Gene Codes Corporation, Ann Arbor, MI, USA) and large hetero-
zygous deletions were analysed using Poly Peak Parser (http://
spark.rstudio.com/yostlab/PolyPeakParser/ accessed September
2014). A hundred and five other homozygous null variants iden-
tified by exome sequencing were validated and confirmed by
comparison to Illumina exome array and/or Illumina Omni Ex-
press genotyping data in Generation Scotland, CROATIA-Korčula
and ORCADES.
Since the Sanger sequencing revealed the importance of se-
quence coverage in calling homozygotes correctly in the exome
dataset (see Results section), we decided to only retain, in our
final set of LOF variants, homozygous mutations that were (a) ei-
ther Sanger confirmed (13 variants) or (b) observed and validated
by previous LOF studies (2,7) (111 variants) or (c) variants that had
a sequence coverage of 20 in at least one homozygous individual
(49 variants). Note that none of our 62 novel variants were ob-
served in the recent Finnish study (12). Except where stated
otherwise, our inter-population comparisons, however, were
performed setting the minimum coverage of these variants to
5, given that the mean sequence depth was only 19 in CRO-
ATIA-Korčula.
GO term enrichment analysis was performed using GOrilla
(18) with 17 424 genes captured by the exome sequencing as the
background set.
Runs of homozygosity (ROHs) were called using array data
that had already been subjected to quality control. Genotyping
was performed using the Illumina HAP300, Omni1 and OmniX
arrays. Individuals with a call rate less than 98% were excluded,
as were SNPs with a call rates less than 98%, minor allele
frequencies of less than 5%, and SNPs failing a test of HWE
(P < 10−6). Autosomal ROHs exceeding 1.5 Mb in length were
called using PLINK, with the following settings: –homozyg-
window-snp 50 –homozyg-snp 50 –homozyg-kb 1500 –homozyg-
gap 1000 –homozyg-density 50 –homozyg-window-missing
5 –homozyg-window-het 1. We extracted HLOFs that were biased
towards being found either within or outside ROHs respectively;
for this means, we used a binomial test with an expected fre-
quency equal to the overall frequency of HLOFs within ROHs (7).
This frequency was calculated separately for each population.
Next, we compared the allele frequencies of the two classes of
HLOFs, i.e. HLOFs biased towards being found mostly within
ROHs (Binomial test: P < 0.1) and those found mostly outside
the autozygome (Binomial test: P < 0.1).
A number of the populations cohorts have been extensively
studied, with a range of clinically relevant quantitative traits
measured; to find possible traits associations, we used a com-
bined dataset, which included all individuals whose exomes
had been sequenced, as well as individuals who had been geno-
typed on Illumina HumanHap300, CNV370, OmniExpress or
Omni1 arrays. The number of traits which we used for analysis
were 867, 455, 194, 444 and 82 in a total of 2426 Orcadians, 1145
CROATIA-Vis islanders, 971 CROATIA-Korčula islanders, 1032
Swedes and 853 individuals of GS:SFHS respectively (Supplemen-
tary Material, Table S2). However, with very small sample sizes
(number of carriers) for most HLOFs, there was limited power to
detect any phenotypic associations; further, if each variant was
to be tested independently, the number of potential tests per-
formed would have been very large (867 traits tested for associ-
ation with 173 variants in ORCADES), leading to spurious
associations. Hence, our main strategy was to relate the overall
mutational burden, i.e. the number of HLOFs carried by a given
individual, to the number of extreme phenotypic values ob-
served, i.e. the number of traits that fell into the bottom or top
1% quantile of the trait distribution for a given individual in a
given population. Using R, we constructed a linear model, using
the number of extreme trait values as a response variable, and,
as predictor variables, the number of HLOFs, as well as the num-
ber of traits measured for an individual (accounting for the fact
that not all individuals were measured for all traits). We per-
formed the analysis separately for each population, and also re-
peated it, removing (1) all olfactory genes or (2) all variants with a
C-score less than 25.
Supplementary Material
Supplementary Material is available at HMG online.
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